Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. (IMNN) generates frequent news as a clinical-stage biotechnology company advancing DNA-mediated immunotherapies and DNA vaccine technologies. Most coverage centers on its lead program, IMNN-001, a TheraPlas-based IL-12 DNA immunotherapy in Phase 3 development for newly diagnosed advanced ovarian cancer, and on its PlaCCine DNA vaccine platform, including the IMNN-101 COVID-19 booster candidate.
Investors following IMNN news can expect regular updates on clinical trial progress, such as enrollment milestones, translational data and survival outcomes from the OVATION 2 Phase 2 study and the pivotal OVATION 3 Phase 3 trial. Company releases describe how IMNN-001 is being evaluated in combination with standard neoadjuvant and adjuvant chemotherapy, and how biomarker data show shifts in the tumor microenvironment toward more active anti-tumor immunity.
Another major news theme is scientific and medical conference activity. Imunon frequently announces posters and presentations at meetings such as the Society for Immunotherapy of Cancer, the European Society for Medical Oncology, the International Gynecologic Cancer Society and specialized ovarian cancer conferences. These items often include new translational data on immune cell changes, cytokine profiles and clinical outcomes associated with IMNN-001.
Imunon also issues news on corporate and financial developments, including quarterly financial results, R&D Day events, capital markets transactions like registered direct offerings and at-the-market equity programs, and Nasdaq listing-related updates. For the PlaCCine platform, news items highlight proof-of-concept data for IMNN-101 and presentations at international vaccine conferences.
For readers tracking IMNN, this news feed provides a consolidated view of clinical milestones, scientific recognition, financing activities and regulatory communications that shape the company’s development trajectory in oncology and DNA vaccine research.
IMUNON (NASDAQ: IMNN) has closed a private placement offering priced at-the-market under Nasdaq rules, securing $3.25 million in initial gross proceeds through the sale of 7,222,223 shares of common stock (or pre-funded warrants) at $0.45 per share. The deal includes short-term warrants to purchase up to 14,444,446 additional shares, which if fully exercised, could generate up to $6.5 million in additional gross proceeds.
The warrants will be exercisable at $0.45 per share following stockholder approval and will expire three years from that date. H.C. Wainwright & Co. served as the exclusive lead placement agent, with Brookline Capital Markets as co-placement agent. The company plans to use the proceeds for working capital and general corporate purposes.
IMUNON (NASDAQ: IMNN) has secured a private placement offering priced at-the-market, raising $3.25 million initially through the sale of 7,222,223 shares of common stock (or pre-funded warrants) at $0.45 per share. The deal includes short-term warrants to purchase up to 14,444,446 additional shares, which could generate up to $6.5 million in additional proceeds if fully exercised.
The warrants will be exercisable at $0.45 per share upon stockholder approval and will expire after three years. The offering, expected to close around May 27, 2025, is being managed by H.C. Wainwright & Co. as exclusive placement agent, with Brookline Capital Markets as financial advisor. The company plans to use the proceeds for working capital and general corporate purposes.
IMUNON (NASDAQ: IMNN) has announced groundbreaking results from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study demonstrated a 13-month increase in median overall survival (46 vs. 33 months) and a 3-month improvement in progression-free survival (14.9 vs. 11.9 months) compared to standard care.
Notably, patients receiving PARP inhibitors alongside IMNN-001 showed exceptional results, with median overall survival not yet reached after 5+ years versus 37 months in the control group. The therapy was well-tolerated with no serious immune-related adverse events. Based on these promising results, IMUNON has initiated its pivotal Phase 3 OVATION 3 Study at two sites.
The findings will be presented at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology.IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, has announced the withdrawal of its Form S-1 Registration Statement (No. 333-286403) with the SEC. The registration statement, originally filed on April 4, 2025, was withdrawn as the company has decided not to proceed with the planned public offering at this time. The statement had not been declared effective by the SEC, and no securities were sold in connection with the offering.